CST, 51434S, Echinomycin

Chemical Modulators for studying in the research area. Product Usage Information Echinomycin is supplied as a lyophilized powder. For a 1 mM stock, reconstitute 1 mg of powder in 0.91 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect. Storage Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles . Background The small-molecule Echinomycin is an inhibitor of hypoxia-inducible factor 1 (HIF1), an important transcription factor controlling the expression of genes that facilitate the response to a hypoxic environment. Cellular response to hypoxia involves angiogenesis, erythropoiesis, cell cycle, metabolism, and apoptosis, all of which are important for metastasis and tumor progression. Echinomycin inhibits HIF-1α and HIF-1β binding to a hypoxia-responsive element sequence of promoters of hypoxia-responsive genes (1). Echinomycin eliminated the ability of mouse lymphoma and human acute myeloid leukemia (AML) cancer stem cells to form colonies, and inhibited human AML in a xenogeneic model through preferential elimination of cancer stem cells (2). Inhibition of HIF-1α by Echinomycin can reduce the effects of acute graft-versus-host disease and extend leukemia free survival following allogeneic hematopoietic stem cell transplantation (3). Echinomycin inhibited adipogenesis and suppressed adipocyte differentiation in 3T3-L1 WAT preadipocytes, which may lead to a new therapeutic approach targeting obesity and diabetes (4). Alternate Names NSC-13502; Quinomycin A